Overview
GHRP-6 is one of the original synthetic growth hormone-releasing peptides, developed in the 1980s by Bowers and colleagues. It is a 6-amino-acid ghrelin receptor agonist that reliably stimulates pulsatile GH release from the anterior pituitary. Unlike its more selective successor ipamorelin, GHRP-6 retains substantial ghrelin-receptor activity in the appetite circuitry, producing meaningful appetite stimulation as a near-universal effect — and as a meaningful clinical differentiator. Multiple human studies in the 1990s and early 2000s characterized its GH-releasing pharmacology; clinical-outcome work for body composition is sparse, and recreational community use has largely shifted to ipamorelin (cleaner side-effect profile) or MK-677 (oral, longer-acting).
Mechanism
Agonist at the growth hormone secretagogue receptor (GHSR-1a, the endogenous ghrelin receptor) at the anterior pituitary and hypothalamus. Drives pulsatile GH release synergistically with GHRH or GHRH analogs (CJC-1295). Substantial ghrelin-pathway activity in the hypothalamic appetite circuit produces hunger and may transiently elevate cortisol and prolactin more than ipamorelin does.
Evidence by indication
We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.
Stimulation of endogenous GH release
Multiple human pharmacology studies (Bowers 1990s, Camanni 1998, Massoud 1996) consistently demonstrate acute GH release after SubQ or IV administration in healthy adults and in older adults. The hormonal effect is well established. Tier 2 because the studies are smaller and the indication is biochemical, not a clinical outcome.
Appetite stimulation / cachexia adjunct
Ghrelin-receptor activation drives appetite — multiple human studies show acute hunger increase after GHRP-6 administration. Mechanistic work supports use in cachexia/anorexia of aging, though large clinical-outcome trials in cachexia have not been completed for GHRP-6 specifically (most cachexia work has moved to anamorelin and other newer ghrelin agonists).
Body composition / fat loss / muscle gain
Recreational use is widespread but not directly studied at clinical-outcome level. Generalizing from acute GH release to sustained body-composition change is mechanism-as-evidence, which Skill Rule 3 cautions against.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Sleep quality
Plausible mechanism via GH/ghrelin sleep effects. No well-designed RCT with sleep as primary endpoint specifically for GHRP-6.
No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.
Studied dose ranges
The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.
Community standard is 100 mcg per dose 1–3× daily, often stacked with a GHRH analog. Doses above ~300 mcg are commonly reported to flatten the GH response (saturable receptor) while exacerbating side effects — more is not better.
Contraindications
- Active malignancy (theoretical concern from sustained GH/IGF-1 elevation)
- Uncontrolled diabetes (insulin resistance worsening with GH spikes)
- Pregnancy and breastfeeding
- Adolescents with open growth plates (use only under endocrinology supervision)
- Significant pre-existing appetite dysregulation (binge eating disorder, etc. — appetite stimulation is meaningful)
- Known hypersensitivity to peptide formulations
Reported side effects
- Significant appetite stimulation / hunger (the defining differentiator from ipamorelin)
- Transient cortisol and prolactin elevation (more pronounced than with ipamorelin)
- Water retention, mild puffiness
- Lethargy or transient flushing post-injection
- Numbness or tingling (rare; consistent with high-IGF-1 carpal-tunnel-like effects with chronic use)
- Reduced glucose tolerance with sustained use
Reconstitution & storage
Lyophilized powder reconstituted with bacteriostatic water. A 5 mg vial in 2.5 mL BAC water = 2 mg/mL, making a 100 mcg dose = 5 units on a U-100 syringe. Use the Juno calculator to verify.
Storage. Lyophilized: refrigerate. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.
Editorial note
DRAFT — pending Wayne's review. GHRP-6 is the older, less selective sibling of ipamorelin. The clinically meaningful differentiator is appetite stimulation — a feature for cachexia or chronic-illness contexts, a side effect for body-recomposition users. Hold the line against the recreational 'better than ipamorelin' framing — there's no human evidence to support that. Most modern users should default to ipamorelin unless appetite stimulation is a goal.
Citations
- [1]On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormoneBowers CY, Momany FA, Reynolds GA, Hong A. · Endocrinology · 1984 · PMID 2156869Foundational pharmacology citation for GHRP-6 as a GH secretagogue.View source
- [2]The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivenessMassoud AF, Hindmarsh PC, Brook CG. · Clinical Endocrinology · 1996 · PMID 8772586Anchor for human GH-release pharmacology of GHRP-class peptides; characterizes saturation and tachyphylaxis.View source
- [3]Growth hormone-releasing peptides and their analogsCamanni F, Ghigo E, Arvat E. · Frontiers in Neuroendocrinology · 1998 · PMID 9710238Cross-indication review supporting Tier 2 GH-release and appetite-stimulation framing across the GHRP class.View source